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Abstract
Background: Tristetraprolin (TTP) is the prototype member of a family of CCCH tandem zinc finger proteins and is
considered to be an anti-inflammatory protein in mammals. TTP plays a critical role in the decay of tumor necrosis factor
alpha (TNF) mRNA, among others, by binding AU-rich RNA elements in the 39-untranslated regions of this transcript and
promoting its deadenylation and degradation.
Methodology/Principal Findings: We used yeast two-hybrid analysis to identify potential protein binding partners for
human TTP (hTTP). Various regions of hTTP recovered 31 proteins that fell into 12 categories based on sequence similarities.
Among these, the interactions between hTTP and CIN85, cytoplasmic poly (A) binding protein (PABP), nucleolin and heat
shock protein 70 were confirmed by co-immunoprecipitation experiments. CIN85 and hTTP co-localized in the cytoplasm of
cells as determined by confocal microscopy. CIN85 contains three SH3 domains that specifically bind a unique proline-
arginine motif (PXXXPR) found in several CIN85 effectors. We found that the SH3 domains of CIN85 bound to a PXXXPR
motif located near the C-terminus of hTTP. Co-expression of CIN85 with hTTP resulted in the increased phosphorylation of
hTTP at serine residues in positions 66 and 93, possibly due in part to the demonstrated association of mitogen-activated
protein kinase kinase kinase 4 (MEKK4) to both proteins. The presence of CIN85 did not appear to alter hTTP’s binding to
RNA probes or its stimulated breakdown of TNF mRNA.
Conclusions/Significance: These studies describe interactions between hTTP and nucleolin, cytoplasmic PABP, heat shock
protein 70 and CIN85; these interactions were initially discovered by two-hybrid analysis, and confirmed by co-
immunoprecipitation. We found that CIN85 binding to a C-terminal motif within hTTP led to the increased phosphorylation
of hTTP, possibly through enhanced association with MEKK4. The functional consequences to each of the members of this
putative complex remain to be determined.
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Introduction
The cellular response to physiological and environmental
stimuli involves regulation of gene expression at multiple levels.
Although transcription is a major site of control, post-transcrip-
tional mechanisms also play pivotal roles in regulating gene
expression. RNA translation and mRNA degradation are
dependent on specific cis-acting sequences and trans-acting factors
[1,2], and expression of the trans-acting regulatory proteins is
controlled at multiple levels.
A crucial level of control is exerted at the level of mRNA decay
in the case of the pro-inflammatory polypeptide tumor necrosis
factor alpha (TNF), one of whose regulators is the CCCH tandem
zinc finger protein tristetraprolin (TTP; also known as ZFP36,
NUP475 and GOS24) [3]. However, the precise mechanisms by
which TTP controls TNF mRNA stability are unclear, with
various data supporting roles for the proteasome, the exosome,
and RNA processing-bodies (P-bodies). TTP, through its CCCH
tandem zinc finger (TZF) domain, first binds to the AU-rich
element (ARE) of the TNF transcript with high affinity to a nine
base sequence, UUAUUUAUU, that is repeated several times in
the TNF mRNA 39-untranslated region (UTR) [4,5,6]. RNA
binding is followed by deadenylation and ultimately transcript
decay [7,8,9,10,11,12,13]. The other three mammalian TTP
family members, ZFP36L1 (also known as TIS11B, BRF1, ERF1,
and CMG1) [14], ZFP36L2 (also known as TIS11D, BRF2, and
ERF2) [15], and ZFP36L3 [16,17] share TTP’s ability to
accelerate the deadenylation and decay of ARE-containing
transcripts in cell transfection studies and in cell-free dead-
enylation assays.
TTP is subject to many modes of regulation, including its
agonist-stimulated induction at the transcriptional level, nucleo-
cytoplasmic shuttling, interactions with cellular proteins, and
phosphorylation. In an attempt to identify some of the protein
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conducted an extensive yeast two-hybrid screen, using full-length
human TTP and its fragments as ‘‘baits’’. Human TTP (hTTP)
fragments bound to regions of 31 proteins that fell into 12
categories based on sequence characteristics. One novel hTTP
binding protein identified by this technique was the adaptor
protein human Cbl-interacting protein CIN85, also known as
Ruk, SETA or SH3KBP1 (SH3-domain kinase binding protein 1).
CIN85 is known to associate with Cbl [18], Src family kinases
[19], p85 phosphatidyl inositol-3 (PI-3) kinase [20] and MEKK4
[21]. The amino-terminus of CIN85 contains three SH3 domains
known to mediate protein–protein interactions by binding to
unique proline-rich motifs. CIN85 is thought to participate in
many important cellular processes including T-cell activation,
kidney function, apoptosis in neuronal cells and endocytosis, in
part by regulating receptor tyrosine kinase (RTK) signaling [22].
We found that binding of CIN85 to hTTP occurred at a proline-
rich motif that was not found in mouse TTP or in the other human
TTP family members; surprisingly, this binding led to increased
phosphorylation of hTTP at serine residues in positions 66 and 93.
Results
Results of Two Hybrid Screen
In an automated two-hybrid screen, full-length hTTP was found
to be self-activating; consequently, a series of protein fragments
was expressed. In some cases, screens for possible hTTP
interacting proteins were performed in the presence of ARE-
RNA fragments derived from the TNF mRNA sequence.
Human TTP fragments were screened against three separate
activation domain libraries, derived from human spleen, brain,
and from a mixture of breast and prostate cancer cell lines. Thirty-
one hTTP fragments were fused with the Gal4 DNA binding
domain. Of these constructs, eight containing amino-terminal
amino acids 1–50 were self-activating; however, eight others,
typically containing the TZF domain, were successful in
recovering interacting proteins. The amino acid sequences of
these interactors were analyzed for identification as described [23].
In total, 31 ‘‘prey’’ interactors were identified that comprised
multiple fragments identified in several separate screens. These
potential interactors fell into 12 different protein categories based
on specific motifs in their sequences. A list of the potential
interactors focused on in this paper is shown in Table 1. These
proteins included other TTP family members, several types of
RNA binding proteins, RNA helicases, the CCR4-NOT1 dead-
enylase, and proline-rich domain containing proteins.
Co-Immunoprecipitation of hTTP with Potential
Interacting Proteins
We selected four potential TTP binding partners, cytosolic poly
(A) binding protein (PABP/PABPC1), nucleolin, heat-shock
protein 70 (HSP70), and CBL-interacting protein 85 (CIN85)
(Table 1), for further validation using co-immunoprecipitations
between hTTP and epitope-tagged candidate proteins in HEK
293 cells. Endogenous, untagged nucleolin co-immunoprecipitated
with Flag-tagged or HA-tagged hTTP (Fig. 1D, lanes 2, 4 and 5),
but not with extracts from cells transfected with plasmids encoding
HA- and Flag-tagged empty vectors (Fig. 1D, lane 1). We also
tested nucleolin binding to cytoplasmic PABP, which we also
identified as a potential interactor with hTTP (Table 1) and
confirmed by co-immunoprecipitation in the present study (Fig. 1F,
lane 4). Nucleolin was pulled down both by hTTP alone and by
PABP alone when they were each immunoprecipitated with anti-
Flag antibody (Fig. 1D, lanes 2 and 3), and by pulldown of hTTP
when it was co-expressed with PABP (Fig. 1D, lane 4). These
results suggest that nucleolin can form complexes with hTTP and
PABP individually, as well as with the complex formed when they
are expressed together. The hTTP did not bind to the negative
control protein, human MARCKS (Fig. 1F, lane 5).
The association between Flag-hTTP and HSP70 was confirmed
when the cell lysate was immunoprecipitated using anti-Flag
antibody and probed with an anti-HSP70 antibody (Fig. 1H, lane
2), confirming HSP70 as a binding partner of hTTP under these
conditions. However, although CIN85 was identified in the two
hybrid screen as a potential interactor with hTTP, the same anti-
Flag immunoprecipitation did not pull down detectable endoge-
nous CIN85 (Fig. 1G, lane 2), prompting further investigation
using overexpression of CIN85 protein. We have been unable to
detect endogenous CIN85 expression in HEK 293 cells, either by
western blotting, using CIN85 antibody HQ-17 (Sigma) (data not
shown) or by northern blotting (see below).
Interaction of Human TTP and CIN85
We investigated a possible association between these two
proteins by transfection and co-immunoprecipitation (Fig. 2A).
The association of hTTP with PABP was used as a positive
control, with the MARCKS protein used as negative control.
Binding of hTTP to CIN85 (Fig. 2A2, lane 4) and to PABP
(Fig. 2A2, lane 6) was readily detected in anti-Flag immunopre-
cipitations. Unexpectedly, the migration of hTTP appeared to be
retarded after co-immunoprecipitation with CIN85 (Fig. 2A2,
compare lanes 4 and 6), raising the possibility that there might be
Table 1. Potential protein interactors with hTTP.
hTTP (aa #) Library (human) Interactor (Accession #) Interactor (aa #) Function
150–326,
223–326.
Brain/Spleen CIN85 (NP_114098.1) 4–264, 4–450. CBL-interacting protein: Endocytosis, signaling,
apoptosis. etc.
90–180 Breast/Prostate cancer Nucleolin (NP_0053722) 375–692 rDNA transcription, rRNA maturation, ribosome
assembly and nucleocytoplasmic transport.
90–180 Spleen PABPC1 (NP_002559) 100–309, 236–399, 99–422,
178–466, 79–400, 95–408.
Translational initiation, mRNA stabilization and
nucleocytoplamic shuttling.
90–180 Breast/Prostate cancer PABPC1 (NP_002559) 1–246, 187–482. Translational initiation, mRNA stabilization and
nucleocytoplasmic shuttling.
90–180 Spleen HSP70 (NP_005337.2) 11–416 Participates in ubiquitin- proteasome pathways.
Amino acid (aa) residue numbers for hTTP were from GenBank RefSeq NP_003398.1. The aa residues shown for potential hTTP-interacting proteins are from the RefSeq
numbers listed in the ‘‘Interactors’’ column in the table.
doi:10.1371/journal.pone.0009588.t001
Tristetraprolin and CIN85
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the co-immunoprecipitation was performed instead with the anti-
HA antibody followed by immunoblotting with the anti-Flag
antibody, both CIN85 and PABP were pulled down as hTTP
binding partners (Fig. 2A4, lanes 4 and 6). There was no apparent
binding of TTP to MARCKS (Fig. 2A2 and 2A4, lane 8). These
results confirmed that both PABP and CIN85 could interact with
hTTP under these experimental conditions, and that the
migration of hTTP was apparently retarded after it had been
co-expressed with CIN85.
Association of CIN85 with Other TTP Family Members
We also did not identify CIN85 in other two-hybrid
experiments with human ZFP36L1, human ZFP36L2, or mouse
ZFP36L3 (data not shown). We therefore co-expressed CIN85
with each of these full-length TTP family members in HEK 293
cells and attempted to co-immunoprecipitate these proteins from
lysates expressing both pairs of proteins. Again, hTTP could be
brought down by CIN85 (Fig. 3A2, lane 4) and by PABP (Fig. 3A2,
lane 10) but CIN85 did not pull down hZFP36L1 (Fig. 3A2, lane
6), hZFP36L2 (Fig. 3A2, lane 8) or mouse ZFP36L3 (Fig. 3B3, lane
4). Thus, we found no evidence of an association between CIN85
and the other human TTP family members ZFP36L1 or
ZFP36L2, or between CIN85 and either mouse ZFP36L3 or
TTP. Once again, CIN85 was able to pull down hTTP as a
positive control (Fig. 3B3, lane 6).
Sites of Interaction in hTTP and CIN85
Since in our two hybrid screen two separate hTTP baits
containing C-terminal hTTP sequences identified multiple clones
representing two fragments of human CIN85 (aa 4–264 and aa
40–458), we predicted that the C-terminal region of hTTP was
involved in its binding to the N-terminus of CIN85. The extreme
C-terminus of hTTP contains a potential CIN85 binding site,
represented by the consensus PXXXPR [21,24,25]. We therefore
tested a series of C-terminal deletion mutants of hTTP against full-
length CIN85 in co-immunoprecipitation assays. The names of
these constructs are indicated at the top of the gel lane in Fig. 4A.
We found that removal of five or eight C-terminal amino acids had
no effect on CIN85 binding (Fig. 4A2, lanes 4–6); however,
Figure 1. Co-immunoprecipitation of hTTP with potential
interacting partners. In this and subsequent figures, extracts were
prepared in RIPA buffer from HEK 293 cells transfected with DNA
encoding the HA- and Flag-tagged expression vectors indicated at the
top of each gel lane by the ‘‘+’’ sign. Total DNA transfected was 5.0 mg
per 100 mm petri dish. For each western blot shown, the immunopre-
cipitating antibody (IP) and the subsequent immunoblotting antibody
(IB) are indicated to the left of each panel, as are the positions of
protein molecular weight standards. The immunoreactive protein
species are indicated by the labeled arrows to the right of each blot.
Each immunoprecipitation used 1 mg of cellular lysate protein as the
starting material. In some cases, the blots are of whole cell lysates (WCL)
(50 mg of total protein per lane) instead of from immunoprecipitations
to confirm expression of the respective protein in the lysates prior to
immunoprecipitation. In addition to the epitope-tag antibodies
indicated, western blotting in this case also used antibodies to
endogenous nucleolin (NCL), CIN85, and HSP70. See the Results section
for additional details.
doi:10.1371/journal.pone.0009588.g001
Figure 2. Interaction of TTP and with PABP and CIN85.
Abbreviations and other details are as described in the legend to Fig. 1.
doi:10.1371/journal.pone.0009588.g002
Tristetraprolin and CIN85
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Fig. 4A2, lane 2) C-terminal amino acids in hTTP, in both cases
removing the PXXXPR motif, completely eliminated the binding,
suggesting that this PXXXPR motif is critical for forming the
complex with CIN85. Equivalent expression of the various mutant
forms of hTTP is documented in Fig. 4A1 (lanes 2–6).
In a separate two hybrid screen conducted using fragments of
mouse TTP (mTTP) as baits, we did not identify CIN85 as an
mTTP interactor (data not shown). Mouse TTP also failed to bind
CIN85 in the co-immunoprecipitation assay (Fig. 4E, lane 6). Since
CIN85 did not bind to mouse TTP or to the other human TTP
family members (Fig. 3A and B), we aligned the C-terminal
sequences of these proteins, and found that the intact PXXXPR
domain did not occur in mouse TTP, but did occur in all other
mammals for which sequence was available (Fig. 4B). That this was
not an artifact of a mouse sequencing error was confirmed by
alignment of the mouse C-terminal protein sequence with ESTs in
GenBank, which demonstrated at least nine mouse ESTs with
identical translated sequence to that shown in Fig. 4B. We also could
not find intact PXXXPR motifs elsewhere in the mouse protein.
We next attempted to define which region of CIN85 was
responsible for binding to hTTP. In its N-terminal region, CIN85
contains three Src homology 3 (SH3) domains, SH3A, SH3B, and
SH3C. The region around amino acid 400 is proline rich, and the
extreme C-terminus contains a coiled-coil domain. The details of a
series of Flag-tagged expression constructs in which some of these
domains were deleted are summarized schematically in Fig. 4C.
Each of these deletion constructs was then separately co-expressed
with full length HA-tagged hTTP. The results from immunopre-
cipitations performed on cell lysates expressing these protein
fragments are summarized in Fig. 4D and 4F. These data
demonstrated that hTTP could bind to all of the N-terminal
CIN85 fragments carrying various combinations of the three SH3
domains (Fig. 4D2, lanes 2–6, 8), and to individual SH3 domains
(Fig. 4F, lanes 1–3), but not to the C-terminal half of CIN85 that
lacked any of the SH3 domains (Fig. 4D2, lane 7). These results
suggest that the binding of CIN85 to hTTP is mediated by the
interaction of the SH3 domains of CIN85 to the PXXXPR motif
located within the C-terminus of hTTP.
In order to further test whether the first proline in the PXXXPR
motif of hTTP is necessary for its binding to CIN85, we changed
the first proline in this motif to valine (P309V). We also replaced
the corresponding threonine with proline (T302P) in mTTP to
recreate the human PXXXPR motif. These expression plasmids
were then transfected into HEK293 cells, and co-immunoprecip-
tations on the resulting lysates were performed using antibodies
against HA or Flag, as described above. As expected, WT hTTP
and CIN85 were co-immunoprecipitated by anti-HA or anti-Flag
antibodies (Fig. 4E3 and 4E4, lane 4 in each case), whereas WT
mTTP did not bring down CIN85 (Fig. 4E3, lane 6). Mutating the
first P in the human PXXXPR motif (P309V) eliminated the
binding of hTTP to CIN85 (Fig. 4E3, lane). Creation of the
PXXXPR motif in mTTP (T302P) permitted the binding of
mTTP to CIN85 (Fig. 4E3, lane 7). The roughly equivalent
expression of the mutant proteins was demonstrated in Fig. 4E1.
PABP was found to associate with both hTTP and mTTP when it
was tested as a positive control (Fig. 4E3, lanes 8 and 9,
respectively). Neither hTTP nor CIN85 was co-immunoprecipi-
tated by empty vector negative controls (Fig. 4E3, lanes 2 and 3).
As before, hTTP expressed in the presence of CIN85 was found to
migrate more slowly than hTTP not expressed with CIN85
(Fig. 4E1, compare lanes 2 and 4). This retarded migration
disappeared in the case of the non-binding TTP mutant P309V
(Fig. 4E1, lane 5), but was present in the newly binding-competent
mouse T302P mutant (Fig. 4E1, lane 7). When the hTTP in the
lysates was dephosphorylated with CIAP, the hTTP protein
migrated to a position roughly corresponding to its predicted size
of approximately Mr 34,000 (Fig. 4E1, lane 10).
These results demonstrate that the PXXXPR motif is
responsible for hTTP’s binding to CIN85, and that the presence
of this intact motif in either human or mouse TTP results in its
retarded migration in SDS gels after co-expression of CIN85.
Human TTP Forms a Complex with MEKK4 and CIN85
Because of the possible increase in hTTP phosphorylation that
occurred upon co-expression with CIN85, we evaluated the
possibility that mitogen-activated protein kinase kinase kinase 4
(NP_005913.2; synonyms: MEKK4 kinase, MAP3K4; FLJ42439;
PRO0412; KIAA0213; MAPKKK4; MTK1; JNK/p38 MAP
kinase kinase kinase MEKK4), a known binding partner and
Figure 3. Association of CIN85 with hTTP family members.
Abbreviations and other details are as described in the legend to Fig. 1,
with the exception of Panel 3B1, which shows an immunoblot of the
whole cell lystate probed with anti-Flag antibody.
doi:10.1371/journal.pone.0009588.g003
Tristetraprolin and CIN85
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presence or absence of CIN85. Confocal microscopy of HEK 293
cells transfected with plasmids expressing hTTP, CIN85, and
MEKK4 proteins showed that hTTP and CIN85 were at least
partially co-localized in the cytoplasm (Fig. 5A), as were CIN85
and MEKK4 (Fig. 5B). We next tested the possibility of
associations among the proteins by co-immunoprecipitation.
When an HA-MEKK4 immunoprecipitation was blotted with
an anti-Flag antibody, then Flag-hTTP was readily detected
(Fig. 6A2, lane 6), demonstrating that that hTTP could associate
with MEKK4 directly. These results were supported by the ability
of Flag-hTTP to bring down HA-MEKK4 (Fig. 6A4, lane 6). An
additional experiment demonstrated that HA-MEKK4 brought
down Flag-labeled wild-type hTTP, as well as the T302P mutant
form of hTTP (data not shown). As expected from previous results
in the literature [21], Flag-CIN85 was found to co-immunopre-
cipitate with HA-MEKK4 (Fig. 6A2, lane 7; Fig. 6A4, lane 7).
When all three proteins were expressed together, anti-HA-
MEKK4 could bring down both Flag-CIN85 and Flag-hTTP
(Fig. 6A2, lane 7), and Flag-hTTP and CIN85 could bring down
HA-MEKK4 (Fig. 6A4, lane 7). These results demonstrate that
both hTTP and MEKK4 can associate with CIN85, and hTTP
can associate with MEKK4, in separate two-protein complexes; in
addition, the three proteins appear to be able to form three-protein
complexes with each other. As before, none of these proteins was
found to bind non-specifically when co-expressed with empty
vectors (Fig. 6A2, lane 2; Fig. 6A4, lane 3).
Co-Expression with CIN85 Results in Retarded Migration
of hTTP
TTP is known to be heavily phosphorylated [8,10,26,27,28,
29,30,31,32,33,34]. In previous experiments, we observed that
Figure 4. Sites of interaction in hTTP and CIN85. In A, Flag-CIN85 was co-expressed with various C-terminal truncated forms of HA-hTTP, as
indicated at the top of the figure. Abbreviations and other details are as described in the legend to Fig. 1. In B is shown a ClustalW alignment of the
putative PXXXPR CIN85 binding motif near the C-terminus of hTTP aligned with the C-termini of TTP from various vertebrate species, as well as with
the TTP family members ZFP36L1 and ZFP36L2 from human. The sequences shown are derived from the following GenBank accession numbers:
human TTP (NP_003398.1), mouse (NP_035886.1), rat (NP_579824.2), chimpanzee (XP_001136016), rhesus (XP_001086084.1), horse (CD536523.1),
sheep (NP_001009765.1), cow (NP_776918.1), dog (XP_541624.2), pig (DY419026), Xenopus tropicalis (Xtrop) (NP_001106542.1) and Xenopus laevis
(Xlaev) (NP_001081884.1) The putative CIN85 binding PXXXPR motif in human and other mammalian TTPs (but not mouse) is boxed. This motif is also
not present in the orthologues from the two frog species. The typical PXXXPR motif is also not present in the in the C-termini of the other human TTP
family members ZFP36L1 (NP_004917) and ZFP36L2 (NP_008818). In C are shown schematic representations of full-length CIN85 and its truncations.
The names of various truncations of CIN85 and their amino acid positions are indicated on the left. Positions of the Src homology domains 3 (SH3) A,
B and C) are indicated in light grey boxes; the proline rich region (P- rich) is shown as a darker grey box; and the C-terminal coiled-coil region is shown
as a black box. The ability of each construct to bind hTTP is indicated on the right. The data supporting this diagram are shown in D and F, with the
transfected plasmids shown at the top of the blot, and with other aspects of the western blots as described in the legend to Fig. 1. Panel 3
documents the expression of full-length hTTP in each WCL (50 mg/lane). In E are shown data from mutations in the PXXXPR motif in hTTP, and the
corresponding sequence in mouse TTP. Abbreviations and other details are as in the legend to Fig. 1.
doi:10.1371/journal.pone.0009588.g004
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bands of approximately Mr 47,000, which collapses with phospha-
tase treatment to its predicted size of Mr 34,000 [26,27,28,35]. As
shown above, when hTTP was co-expressedwithCIN85, the hTTP
protein had an apparently greater Mr than the protein expressed
alone, or expressed with another binding partner such as PABP
(Fig. 2A2, lanes 4 and 6, Fig. 4D3, lane 2, Fig. 4E1, lanes 4 and 7,
and Fig. 6A1, lane 4), suggesting that hTTP is hyper-phosphory-
lated in response to its interaction with CIN85. This result was seen
in many independent experiments (Fig. 6B3, lanes 2, 4 and 8).
Similar retarded migration was seen when hTTP and CIN85 were
co-expressed with MEKK4 (Fig. 6B3, lane 10).
Co-Expression of CIN85 with hTTP Results in Increased
Phosphorylation of hTTP at Serine Residues 66 and 93
Since the co-expression of hTTP with CIN85 produced an
increase in the apparent Mr of hTTP on SDS/PAGE, suggesting
increased phosphorylation, we analyzed the phosphorylation state
of hTTP using FLAG-affinity-purified protein from HEK 293 cells
expressing FLAG-hTTP alone or Flag-hTTP and HA-CIN85
together. Analyses for phosphopeptide identification were per-
formed using a variety of mass spectrometric, affinity and
chromatographic techniques including ESI-MS and MS/MS as
well as metal oxide affinity chromatography and reverse-phase
liquid chromatography. After phosphopeptides were identified, LC-
ESI-MS runs of hTTP digests from cells with and without co-
expression of CIN85 were performed in efforts to estimate relative
amounts of phosphorylation at each of the identified sites. We
identified two phosphopeptides, SCGWVPPPPGFAPLAPR and
LGPELSPSPTSPTATSTTPSR (serines in bold type represent the
phosphorylated residues), in which the site of phosphorylation could
be unambiguously assigned to Ser 66 and Ser 93, respectively. We
identified a third phosphopeptide, QSISFSGLPSGR (serines in
italics represent the residues at which the phosphorylation could be
occurring), that contained a single phosphorylation, but we could
not determine whether the phosphorylation occurred on Ser 184 or
Ser186.Overallcoverage oftheproteinwasapproximately50%for
the hTTP-only sample, and ,40% for the hTTP plus CIN85
sample. Phosphorylation at Ser 66 was increased several-fold in the
presence ofCIN85(Fig. 7A) and moderately atSer93 (Fig.7B). The
additional site at either Ser 184 or Ser 186 did not appear to be
affected by the co-expression of CIN85 (Fig. 7C). We previously
identified Ser 66 and Ser 93 as potential phosphorylation sites for
PKCm and p38 protein kinase, respectively, as predicted by (http://
scansite.mit.edu) (Cao et al., 2007). Evaluation of these and the
other sites by a variety of programs (http://bioinformatics.lcd-
ustc.org/PPSP/; 22 http://www.cbs.dtu.dk/services/NetPhosK/;
http://scansite.mit.edu/) suggested that Ser 66 could in addition be
a site for MAPKAP kinase 2, and that Ser 93 could also be a site for
cyclin-dependent kinase 5.
Although the extent of phosphorylation in the peptide
QSISFSGLPSGR does not appear to change in response to
CIN85 co-expression, to our knowledge neither Ser 184 nor Ser
186 has been previously characterized as phosphorylated. The
same predictive programs used for Ser 66 and Ser 93 suggest that
phosphorylation of Ser 186 could represent a site for AMP-
dependent kinase, calcium calmodulin dependent kinases, MAP-
KAP kinase 2 and MAP kinase kinase kinase. Meanwhile, Ser 184
is predicted to be a potential site for MAP kinase kinase kinase,
protein kinase A, and various protein kinase C isoforms.
Figure 5. Localization of hTTP and MEKK4 with CIN85 in cultured cells. In A, HEK 293 cells were transfected with plasmids for the expression
of HA-hTTP (red) and Flag-CIN85 (Green), or (B) HA-MEKK4 (red) and Flag-CIN85 (green). The cells were stained with primary antibodies, either an anti-
HA polyclonal or anti-Flag monoclonal, followed by the secondary antibodies Alexa 594 anti-rabbit (red) or Alexa 488 anti-mouse (green),
respectively. Nuclei (blue) were stained with DAPI. The cells were visualized and images obtained by confocal microscopy. The merged images of two
protein signals, indicating areas of apparent co-localization, are shown in yellow.
doi:10.1371/journal.pone.0009588.g005
Tristetraprolin and CIN85
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The RNA binding activity of hTTP is essential for initiation of
mRNA decay. To determine whether there was any effect of the
interaction between CIN85 and hTTP on RNA binding of hTTP,
we performed RNA gel shifts using cytosolic extracts containing
varying concentrations of hTTP alone or together with CIN85,
using a TNF-based ARE RNA probe containing four clustered
UUAUUUAUU motifs (residues 1309–1332, GenBank accession
number NM_013693.2) [8]. Incubation of this probe with a
cytosolic extract prepared from HEK 293 cells transfected with
vector alone (BS) revealed the formation of at least one faint band
representing interactions of the RNA probe with an endogenous
293 cell protein (Fig. 8A, lane 2; arrow points to the non-specific
complex). An extract from cells transfected with the HA-hTTP
expression construct was diluted with an otherwise identical
extract from cells transfected with vector alone that contained the
identical concentration of protein; the percentage of this combined
extract that contained the TTP-containing extract is indicated at
the top of the Fig. 8A. A sample containing 100% hTTP-
expressing lysate produced a single, broad, dark hTTP-ARE
complex (Fig. 8, lane 3). Lysates expressing decreasing proportions
of hTTP exhibited less binding overall, with at least two hTTP-
ARE complexes becoming visible (lanes 5–7). The identical
experiment was repeated in the presence of a constant amount
of CIN85 (Fig. 8A, lanes 9–14). CIN85 alone did not appear to
bind significantly to this probe (Fig. 8A, lane 14), nor did it appear
to alter the binding of the various concentrations of hTTP (Fig. 8A,
lanes 9–11). We confirmed that these complexes contained HA-
hTTP by supershift analysis with the anti-HA and anti FLAG
antibodies (Fig. 8B). Flag-CIN85 alone did not form a complex
with the ARE probe (Fig. 8B, lane 4), as confirmed by the absence
of a supershift when the same extract was incubated with the anti-
FLAG antibody (Fig. 8B, lane 6). In extracts containing both HA-
hTTP and Flag-CIN85, the anti-HA antibody caused a supershift
of the hTTP-probe complex (Fig. 8B, lane 8), whereas the anti-
FLAG antibody did not cause a supershift (Fig. 8B, lane 9). Fig. 8C
documents the immunoreactive expression of both epitope-tagged
proteins; each lane contained five times more hTTP and CIN85 as
in Fig. 8A (lane 3 for hTTP alone), Fig. 8A, lane 9 (hTTP and
CIN85 together), or Fig. 8A, lane 14 (CIN85 alone).
Co-Expression of CIN85 with hTTP Does Not Affect
Destabilization of TNF mRNA
To determine whether co-expression of CIN85 with hTTP
affected the latter’s ability to promote destabilization of a TNF-
based RNA transcript, we used a co-transfection assay described
previously [8]. When cells were transfected with a TNF-based
‘‘target’’ expression plasmid alone, the transcript was detected as a
single band (Figs. 9A1 and 9A2, lanes 2 and 8). When a low
concentration of transfected hTTP plasmid DNA was used (5 ng
per plate; Figs. 9A1 and 9A2, lane 3), TNF mRNA accumulation
was decreased to ,10 to 20% of that of control, as quantified by
Phosphorimager scanning. This decrease in mRNA levels was
accompanied by the appearance of a smaller species of mRNA
transcript, which first became apparent at 5 ng of DNA (Figs. 9A1
and 9A2, lane 3) but was more evident at 50 ng (Figs. 9A1 and
9A2, lane 4). Most of the TNF transcript was in this smaller form,
considered to be the deadenylated form, with increasing amounts
of transfected hTTP DNA, beginning at 50 ng (Figs. 9A1 and
9A2, lane 4) through all higher concentrations used (Figs. 9A1 and
9A2, lanes 5 and 6). However, as shown previously, the total TNF
transcript accumulation increased substantially at higher concen-
trations of DNA to reach a maximum of around 200% (Fig. 9B) of
that of control at 500 ng of transfected hTTP DNA, a
phenomenon we have attributed to protection of the deadenylated
species of RNA by high concentrations of TTP [8]. This is
considered to be a non-physiological artifact from high TTP
concentrations. When the hTTP expression plasmid was co-
transfected with the expression plasmid for CIN85, there was
essentially no effect on this dose-response curve (Figs. 9A1 and
9A2, lanes 8 to 12). Endogenous CIN85 mRNA was undetectable
by this northern analysis (Fig. 9A4, left panel, lanes 1–6). The
phosphorimager values from the TNF mRNA northern blot
Figure 6. Interaction between hTTP and both MEKK4 and
CIN85. In A, tagged expression constructs of MEKK4, CIN85 and hTTP
were co-transfected in pairs (lanes 1 to 7) or together (lane 8) with or
without empty vectors. Abbreviations and other details are as described
in the legend to Fig. 1. In B are shown whole cell lysates, demonstrating
the protein expression from the various expression plasmids or empty
vectors, as well as the apparent shift in the Mr of hTTP when co-
expressed with CIN85.
doi:10.1371/journal.pone.0009588.g006
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expression of hTTP and CIN85 mRNAs is shown in Figs. 9A3 and
9A4, as well as the expression of the endogenous GAPDH mRNA
(Fig. 9A5) used as a gel loading control.
Discussion
The anti-inflammatory and cytokine mRNA regulator TTP is
an immediate-early gene that is induced by stimuli such as growth
factors and mitogens [36,37]. It is an mRNA binding protein that
can promote rapid degradation of mRNA by first binding to AU-
rich elements in the mRNA, often in the 39-untranslated region,
and then stimulating deadenylation and ultimately the decay of the
target transcript [3,38,39,40,41,42,43]. TTP activity can be
regulated at many levels: gene expression; mRNA stability;
nucleocytoplasmic shuttling; phosphorylation; protein binding;
and others. Both TTP and the pro-inflammatory cytokine TNF
can be induced in macrophages by environmental stimuli such as
lipopolysaccharides, and by TNF itself; TTP can, in turn, promote
the downregulation of TNF by directly targeting its transcript [40].
TTP has long been known to be phosphorylated, in some cases
in response to external stimuli; this modification has been shown in
some reports to impair its ability to stimulate mRNA decay
[28,30,31,32,44,45,46,47]. TTP activity is also thought to be
regulated by binding proteins, including Ccr4, Dcp, Xrn1 [48],
MK2 [31], 14-3-3 [49], RISC components Ago/eiF2C [50],
nuclear pore protein Nup214 [51] and PP2A [33]. However, a
thorough knowledge of TTP’s protein binding partners will be
important for a complete understanding of its physiological
regulation.
We have begun to identify potential TTP-interacting proteins
using a series of yeast two-hybrid screens. As described here, this
method uncovered direct physical interactions between human
TTP (hTTP) and CIN85, the cytoplasmic polyA-binding protein
PABP (PABPC1), nucleolin, and HSP70, in addition to 27 other
proteins belonging to various protein classes. Since the N-terminal
region of hTTP was self-activating in the two-hybrid system, most
interactors were recovered with bait peptides encompassing
hTTP’s TZF domain and its C-terminal proline-rich region.
The interactors were recovered from three separate screens using
three different activation domain libraries, derived from human
spleen, human brain, and from a mixture of human breast and
prostate cancer cell lines. As reported here, CIN85 was recovered
by binding to C-terminal fragments of hTTP, whereas the TZF
domain identified cytosolic PABP, HSP70 and nucleolin.
Although the focus of this paper is on the interaction between
TTP and CIN85, the other interactions validated may be of
physiological importance. Nucleolin is a major nucleolar protein
involved in the regulation of ribosome biogenesis, control of
organization of nucleolar chromatin, nucleogenesis [52] and
nucleocytoplasmic transport [53]. Its significance as a binding
partner of TTP is not clear, although TTP is known to be a
nucleocytoplasmic shuttling protein [54,55,56]. HSP70 and its
family members mediate the folding of newly translated proteins in
the cytosol and organelles [57,58] and also have been reported to
promote ARE-mediated mRNA decay [59,60]. The heat-shock
proteins can stimulate the production of certain cytokines (TNF,
IL-1, IL-6 and IL-12) and have been reported to possess potent
immunoregulatory functions [61,62].
The PABP proteins comprise a small nuclear isoform and a
conserved set of at least three functional proteins: Cytosolic PABP
(PABP1 or PABPC1), inducible PABP (iPABP, or PABPC4), and
PABP3 (PABPC3). In our screens, PABPC1 (NP_002559) was
identified and confirmed as a direct binding partner of TTP, even
in cellular lysates depleted of RNA by RNAse digestion. PABP
apparently bound to the TZF domain of TTP, using its C-terminal
region, in both the presence and absence of co-transfected ARE-
containing RNA. Interestingly, certain non-RNA binding mutants
of TTP could still interact with PABP in co-immunoprecipitation
experiments, despite the fact that the TZF domain is thought to be
the RNA binding domain. PABP is a nucleocytoplasmic shuttling
protein [63] that can function both as inhibitor of mRNA
deadenylation and as an enhancer of translation by simultaneously
binding to poly(A) tails of cellular mRNAs and to the eukaryotic
translation initiation factor 4G (eIF4G). This interaction allows for
the formation of circular mRNA loops by providing sites of
interaction for PABP and eIF4E [64,65], and ultimately promotes
both mRNA stability and protein translation. These studies
suggest that TTP not only functions in the mRNA deadenylation
and decay processes previously known to be affected by PABP, but
may also be involved in the mRNA translation events influenced
by PABP. As suggested previously by Wilusz et al., 2001 [66] it is
possible that a physical interaction between TTP, already bound
to its target mRNA, and PABP, could lead to dissociation of PABP
from the poly(A) tail, making the tail more accessible to 39-59
exonucleases and thus accelerated decay.
In the two hybrid screens, two fragments of hTTP (aa 150–325
and aa 223–326) from the C-terminal region pulled out several
partial prey clones of CIN85, corresponding to the N-terminal
fragments aa 4–264 and aa 4–450. The interaction of human TTP
with CIN85 was validated in co-immunoprecipitation experiments
in HEK293 cells. Binding of full-length CIN85 to TTP required an
intact C-terminal PXXXPR motif in the TTP protein, a motif
shown to interact with the N-terminal SH3 domain of CIN85.
Surprisingly, mouse TTP (mTTP), as well as other human and
mouse members of the TTP family (hZFP36L1, hZFP36L2, and
mZFP36L3), all lack this sequence. They also failed to bind to
CIN85 in the two-hybrid screen or in the co-immunoprecipitation
assays. However, when we replaced the threonine in the corres-
ponding sequence in mTTP with proline (T302P), to recreate the
human PXXXPR motif, it permitted the binding of mTTP to
CIN85. Moreover, changing the first proline in this motif to valine
(P309V) in hTTP eliminated the binding of hTTP to CIN85. These
results suggested that CIN85 binding is specific to human TTP
among the human TTP family members, and does not occur
normally in the mouse. However, the PXXXPR binding motif is
present in TTP in all other mammals tested, including rat.
In this study, binding of CIN85 to hTTP did not appear to alter
the binding of hTTP to an ARE-containing RNA probe, nor did it
alter the effect of TTP on the stability of a TNF-based mRNA
probe. One possibility is that binding of TTP to CIN85 may affect
the function of CIN85. For example, CIN85 can regulate the
activity of the protein kinaseMEKK4, by alleviating auto-inhibition
Figure 7. Phosphorylation sites in hTTP co-expressed with CIN85. Panels A, B, and C are extracted ion chromatograms (EICs) for residues 66–
82 (A), 83–103 (B), and 183–194 (C) generated from nanoLC-ESI-MS runs derived from tandem MS data of ions m/z 915.4, m/z 1083.5, and m/z 658.5,
corresponding to the phosphorylated peptides 66–82, 83–103, and 183–194, respectively (Data/Fig. not shown). The normalized responses
demonstrated in the EICs are an estimation of the abundance of the ion of interest. The currents from the non-phosphorylated peptides are
represented as solid lines, and the ion currents attributed to the phosphorylated forms of the same peptides are shown as dashed lines. Duplicate
technical replicates yielded similar results.
doi:10.1371/journal.pone.0009588.g007
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activation of protein kinase pathways such as the p38 MAP kinase
pathway, involving MKK3, MKK4 and MKK6, and the JNK
pathway, through MKK7 or MKK4 [21,67,68]. MKK4 and
MKK7 can phosphorylate and activate JNK, whereas MKK3 and
MKK6 can phosphorylate and activate the p38 MAPK [67].
Figure 8. Effect of co-expressed CIN85 on hTTP binding to an RNA probe. Cytosolic extracts of HEK293 cells transfected with vector alone
(BS), or vectors expressing HA-hTTP alone and Flag-CIN85 alone, were used in RNA gel shift analysis, using a 59 biotin-labeled TNF-ARE based RNA
probe. In A, protein extracts of containing decreasing amounts of HA-hTTP incubated in the presence or absence of a constant concentration of
FLAG-CIN85 were incubated with 0.6 ng of the RNA probe. The migration positions of the hTTP-ARE complexes, the non-specific complexes seen in
the HEK 293 cell extract alone, and the RNA probe alone, are all indicated with arrows to the right of Fig. 8A. In B, 2 mg of cellular protein from FLAG-
CIN85 expressing cell extracts was incubated with or without HA-hTTP or FLAG-hTTP (1.6 mg) in the presence or absence of the respective epitope
tag antibodies. Arrows to the right of the panel are the same as in A, except for the addition of an arrow pointing to the hTTP supershifts. In C,
immunoblots were performed using 10 mg of cellular protein from the same extracts, demonstrating expression of the epitope-tagged proteins.
doi:10.1371/journal.pone.0009588.g008
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plasmid was co-transfected into HEK 293 cells (lanes 2–6, 8–12) with either vector alone or with the indicated amounts of an hTTP expression
construct in the presence or absence of 2 mg of a CIN85 expression construct. Total cellular RNA was harvested 24 h later, and used for northern
blotting. Each lane was loaded with 10 mg of total RNA. Lanes 1 and 7 were from mock-transfected HEK 293 cells. Lanes 2 and 8 were from cells
transfected with vector alone (BS+;5mg/plate). Lanes 3–6, were from cells co-transfected with CMV.mTNF (1 mg) and CMV.hTTP.tag (0.005, 0.05, 0.1,
and 0.5 mg/plate, respectively). Lanes 9–12 were from cells co-transfected with CMV.mTNF (1 mg) and CMV.CIN85.tag (2 mg) and CMV.hTTP.tag (0.005,
0.05, 0.1 and 0.5 mg/plate, respectively). Vector was also added as needed to make the total amount of co-transfected plasmids 5 mg/plate in each
case. As indicated, the northern blots were probed with either a
32P-labeled mTNF cDNA probe (panels 1 and 2, duplicate experiments), an hTTP
probe (panel 3), a CIN85 probe (panel 4) or a GAPDH probe (panel 5). Film exposure was 4 h and 7 h, respectively, for panels, A1 and A2 for filters
hybridized with an mTNF probe. All other filters were exposed to films for 7 h. The two parallel lines labeled TNF indicate the two species of TNF
mRNA discussed in the text. The positions of the 18S rRNA are indicated. In B are shown the phosphorimager values for both species of TNF mRNA as
a function of various TTP plasmid amounts, transfected with or without the CIN85 vector. The graph in B is from a single experiment, but is
representative of three similar experiments.
doi:10.1371/journal.pone.0009588.g009
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of oxidative and environmental stress such as osmotic shock, UV
irradiation, wounding, and exposure to inflammatory factors
[21,67,68,69]. MEKK4 can also bind to TNF-receptor-associated
factor (TRAF4) in TNF receptor signaling cascades, and to MAPK
in cytokine signaling [67]. CIN85 can also activate other kinases,
including Src family kinase-Cbl, activated receptor tyrosine kinases
(RTKs), and the p85a subunit of phosphatidylinositol 3-kinase (PI3-
Kp 8 5 a) [18,20,70,71,72,73].
One interesting finding from this study is that the interaction of
hTTP with CIN85 led to an increase in TTP phosphorylation;
specific residues whose phosphorylation was increased following
CIN85 binding included Ser 66 and Ser 93. Strikingly, the
electrophoretic shift resulting from this phosphorylation occurred
when CIN85 binding activity was restored in mTTP, with the
T302P mutation, and the electrophoretic shift was lost from hTTP
after mutating the CIN85 binding site. This increase in hTTP
phosphorylation upon CIN85 binding led us to investigate the
possibility that a CIN85-activated protein kinase might be
involved in a three-way complex with hTTP. This was indeed
the case, since both hTTP and MEKK4 appeared to associate
with CIN85 in separate two-protein complexes, and hTTP was
found to associate with MEKK4 in the absence of exogenous
CIN85. The three proteins together appeared to form a three-
protein complex. Interestingly, the interaction of hTTP with
MEKK4 in the absence of CIN85 did not appear to lead to the
same enhanced phosphorylation of hTTP, suggesting that CIN85
binding is required for these phosphorylation events to occur.
Binding of hTTP by CIN85 may increase the phosphorylation
of hTTP by several possible mechanisms, including (1) altering the
conformational structure of TTP to make it a better kinase
substrate; or (2) recruiting protein kinases to the vicinity such as
MEKK4. This mechanism remains to be worked out. Also unclear
is the effect of this binding and increased phosphorylation of hTTP
on its activity or function. In our assays, the hyperphosphorylated
hTTP appeared to bind relatively normally to an ARE-containing
RNA probe, and to promote normally the destabilization of a
TNF transcript-based, ARE-containing RNA probe in the co-
transfection assays. These relatively crude assays cannot rule out
minor effects on quantitative aspects of these hTTP activities. It
may be that the hyper-phosphorylation of hTTP at these serine
residues affects hTTP’s intrinsic stability in cells, or its interactions
with other proteins. These and other possibilities will require
further investigation.
Materials and Methods
Yeast Two Hybrid Screening
Automated two-hybrid screening using ProNet technology was
performed by Myriad Genetics, Salt Lake City, UT, as previously
described [74,75]. To construct ‘‘bait’’ plasmids expressing hTTP
or its fragments fused to the yeast Gal4 DNA binding domain,
fragments of hTTP of approximately 150 to 300 base pairs in length
that spanned the entire protein coding region of hTTP were
amplified by PCR, and were transformed together with Gal4 DNA
binding domain vector DNA into a yeast strain with a mating-type
locus designated MAT (MATa trp1-901 leu2-3,112 ura3-52 his3-200
ade2 gal4D gal80) and selected on -Trp plates. Self-activating clones
were identified by mating with empty activation domain vector in a
MATa strain (MATa trp1-901 leu2-3,112 ura3-52 his3-200
gal4Dgal80 LYS2:GAL-HIS3 GAL2-ADE2 met2::GAL7-lacZ)
and were eliminated in the process.
Several different ‘‘prey’’ libraries encoding potential TTP-
interacting proteins were used. These were constructed from
poly(A)+ RNA derived from the following sources: Mixed human
breast cancer and prostate cancer cell lines, in a library containing
approximately 80 million clones; a normal human spleen library of
11 million clones; and a normal human brain tissue library of 60
million clones. In each case the library was cloned downstream of
the Gal4 activation domain (residues 768–881). MATa baits were
mated with MATa prey and selected on -Trp, -Leu, -His, -Ade
plates. His and Ade selections were used to isolate bait/prey
interactions. DNA extracted from yeast colonies was used to
transform E. coli, and bait plasmids were recovered through
kanamycin selection and prey plasmids by ampicillin selection.
Plasmids were re-transformed into yeast, and interactions were
confirmed by liquid b-galactosidase assays. The prey clones were
identified by DNA sequencing. DNA encoding an ARE-contain-
ing RNA derived from TNF ARE RNA (bp 1341–1364 of
GenBank accession number NM_000594.2) was cloned down-
stream of ADH and CYC1 promoters in a plasmid with a URA3
auxotrophic marker gene. Yeast carrying ‘‘bait’’ and RNA
expression plasmids were selected on –Trp, -Ura plates and
screened as above.
Plasmid Constructs
The epitope tag derived from influenza virus hemaglutinin
protein [76] was fused to the last amino acid of hTTP cDNA by
the PCR primer-overlapping mutagenesis technique and sub-
cloned into the HindIII site of vector CMV.BGH39/pBS+ to
generate HA-hTTP as described [8]. Full-length cDNAs for
human CIN85, ZFP36L1, and ZFP36L2 were sub-cloned into
CMV.BGH39/BS+ and modified with amino-terminal RGS-6His-
tags and carboxyl-terminal epitope tags, either HA or FLAG, by
insertion of oligonucleotide linkers into HindIII and ApaI digested
CMV.BGH39/BS+ to create vectors pCMV-FLAG-BGH39 and
pCMV-HA-BGH39, respectively. Restriction endonuclease
BamH1 and XbaI sites were inserted into pCMV-BGH39.A
cDNA clone for CIN85 (clone ID 3906722) was obtained from the
I.M.A.G.E. consortium through Open Biosystems (Huntsville,
AL). The mouse ZFP36L3 (pFlag-muL3) has been described [17].
Expression constructs of HA or FlagTagged Poly-A binding
protein (PABP) (GeneBank accession number BC015958) were
created by RT-PCR using total cellular RNA from HeLa cells
(ATCC catalog number CCL-2) as a template for reverse
transcription and were cloned into the Asp718 and XbaI restriction
sites of CMV.BGH39/BS+. Expression plasmids for mouse HA-
TTP and the plasmid construct CMV.mTNF-a have been
described [8]. The C-terminal deletion expression constructs of
HA-hTTP, namely, HA-hTTP 1-322, HA-hTTP 1-319, HA-
hTTP 1-313, and HA-hTTP 1-290, were kindly provided by Dr.
Wi S. Lai in our laboratory and were similarly generated by PCR
using human WT HA-hTTP as a template and sub-cloned into
the HindIII site of the vector CMV.BGH39/pBS+ as described
above [8]. Expression plasmids HA-hTTP/P309V and HA-
mTTP/T302P were generated by using WT HA-hTTP and
WT HA-mTTP respectively, in a kit from QuickChange Site-
Directed Mutagenesis (Stratagene, La Jolla, CA). Correct
sequences of all plasmid inserts were confirmed by dRhodamine
Terminator Cycle Sequencing (Perkin-Elmer Life Sciences,
Boston, MA).
An HA-MEKK4 expression plasmid was a gift from Dr. Gary
Johnson, University of North Carolina at Chapel Hill, NC, and
has been described [77]. Expression plasmids for Flag-CIN85 and
its deletion constructs have been described [18] and were gifts
from Dr. Sachiko Kajigaya, National Heart, Lung and Blood
Institute, National Institutes of Health, Bethesda, MD. The
expression plasmid HA-MARCKS (pBS-CMV/H80K-HA) was
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fragment of human MARCKS containing the entire protein
coding region with an attached HA-tag into the ECOR1/HindIII
sites of pBS-CMV. The glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) cDNA has been described [40].
Cell Transfections, Immunoprecipitations and Western
Blotting
HEK 293 cells (ATCC catalog number CRL-1573) were
maintained in Minimum Essential Medium (MEM; Invitrogen)
supplemented with 10% fetal bovine serum, 100 U/ml penicillin
and 100 mg/ml streptomycin. Transient transfection was per-
formed using a standard CaPO4 procedure as described [8].
Briefly, 0.2 – 0.5 mg of plasmid DNA was transfected together with
carrier pBluescribe SK- (pBS) DNA to make a total of 5 mg per
100 mm dish. Sixteen h after the addition of DNA, cells were
washed twice with MEM at 37uC, and replenished with fresh
complete medium.
After a further 24 h of incubation, cells were washed twice with
ice-cold phosphate-buffered saline (PBS), and all liquid was
removed by aspiration. Cells were lysed by direct addition to the
culture dish of 600 ml/10 cm dish of one of two buffers. The first
was a radioimmunoprecipitation assay (RIPA) buffer (150 mM
NaCl, 1% (v/v) nonidet P-40 (NP-40), 0.5% (w/v) sodium
deoxycholate, 0.1% (w/v) sodium dodecyl sulfate, 50 mM Tris-
HCl, pH 7.5) supplemented with protease inhibitors (0.2 mg/ml
leupeptin, 0.2 mg/ml pepstatin and 0.5 mM 4-(2-Aminoethyl)
benzenesulphonyl fluoride (ICN Biochemicals, Costa Mesa, CA)).
Cell debris and buffer were scraped from the plate on ice and
extracted for a further 30 min by tumbling at 4uC. Extracts were
clarified by centrifugation at 100,0006g for 45 min at 4uC. NP-40
extracts were prepared as follows: Cells were scraped from 10 cm
dishes, combined and sedimented at 6006g for 3 min at room
temperature. PBS was aspirated and cells were gently resuspended
in a second buffer, NP-40 hypotonic lysis buffer (0.2% (v/v) NP-40,
10 mM KCl, 3 mM MgCl2, 10 mM Hepes-NaOH, pH 7.6)
supplemented with protease inhibitors as above, and incubated on
ice for 15 min. Complete lysis was confirmed by light microscopy of
cells exposed to trypan blue. Extracts were clarified by centrifuga-
tion at 22,0006g for 15 min at 4uC, the KCl concentration was
adjusted to 50 mM, and glycerol was added to a final concentration
of 10% (v/v). All extracts used in immunopurification assays were
treated with RNase. None of the extracts used in this study was
frozen prior to immunoprecipitation. Remaining extracts were
stored at –80uC for immunoblotting.
For immunoprecipitation, 1 mg of cellular protein in 1 ml of
extract in RIPA buffer was incubated at 4uC with 4 mg (20 ml) anti-
FLAG (Sigma, St. Louis, MO) or anti-HA (F-7, Santa Cruz
Biotechnology, Santa Cruz, CA) monoclonal antibody overnight,
and then added to 100 ml (packed volume) protein A Sepharose 4B
beads (Pharmacia, Uppsala, Sweden) and mixed on a rotator (BD,
Franklin Lakes, NJ) for 3 to 4 h at 4uC. Beads were washed by
centrifugation at 10006g for 1 min 3 times with 1 ml of lysis
buffer. SDS sample buffer was added directly to the beads.
Western blotting was performed using 50 mg of protein in cellular
extracts mixed with a 1/5 volume of 56SDS sample buffer, boiled
for 3 min, and then loaded onto SDS–10% PAGE gels. Western
blotting was performed by standard techniques. Membranes were
incubated in Tris-buffered saline–0.5% Tween 20 with either
polyclonal antiserum HA.11 (1:2,500), or with anti-FLAG antibod-
ies directly coupled to horseradish peroxidase, as appropriate. In
some instances, other rabbit polyclonal antibodies were used,
including anti-nucleolin (C23, Santa Cruz Biotech. Inc., Santa
Cruz, CA), anti-HSP70 (K-20 from Santa Cruz) or anti-CIN85
(HQ-17, Sigma). Incubation of membranes with secondary anti-
bodies and development were as described elsewhere [39].
Immunofluorescence and Confocal Microscopy
For immunostaining, cells were cultured on glass cover slips
(Ted Pella Inc; Redding, CA) and transfected with the FLAG- or
HA-tagged constructs using the Fugene 6 reagent (Roche Applied
Science). Two days after transfection, cells were washed twice with
PBS and fixed with 3.7% (v/w) formaldehyde for 10 min at room
temperature, permeabilized with 0.5% (v/v)Triton X-100, and
stained with mouse anti-FLAG monoclonal antibody M2 (Sigma)
and rabbit anti-HA polyclonal antibody Y-11 (Santa Cruz
Biotechnology), followed by fluorescein isothiocyanate-labeled
goat anti-mouse secondary antibody Alexa Fluor 488, or
rhodamine-conjugated goat anti-rabbit secondary antibody Alexa
Fluor 594 (Invitrogen), as appropriate. The stained cells were
mounted with DAPI-VECTASHIELD mounting medium with 49,
6-diamidino-2-phenylindole (Vector Laboratories) to visualize the
nuclei. Stained proteins were visualized by confocal microscopy
using a FluoView
TM laser scanning epi-fluorescence Olympus
FV1000 microscope.
Northern Blotting
For northern analysis, HEK 293 cells were transfected as
described above. Twenty-four hours after the removal of the
transfection mixture, total cellular RNA was harvested using the
illustra RNAspin mini RNA isolation kit (GE Healthcare,
Buckinghamshire, UK). Northern blots were prepared as de-
scribed elsewhere [8]. Blots were hybridized to a randomly
primed, a-
32P-labeled mTTP cDNA [8] or a ,1-kb NarI-BglII
fragment of mTNF cDNA. Some blots were also hybridized
with an a-
32P-labeled glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA probe [40] or with a 570-bp PCR product
(nucleotides 634–1203; GenBank accession number NM_031892)
of a CIN85 cDNA [18].
RNA Electrophoretic Mobility Shift Assay
Cytosolic extracts (2 mg of protein) prepared from HEK 293
cells transfected with vector alone, or with expression constructs
driven by the CMV promoter, were incubated with 0.6 ng of 59
biotin-labeled human TNF-ARE probe (Invitrogen Corp, CA) at
room temperature for 20 min in 20 ml of lysis buffer (without
protease inhibitors) containing 10 mM Hepes (pH 7.6), 40 mM
KCl, 2.5% (v/v) glycerol and 3 mM MgCl2. Heparin and yeast
tRNA were added to final concentrations of 2.5 mg/ml and 50 ng/
ml, respectively, for an additional 10 min. RNA not associated with
protein was digested with 100 U of RNase T1 for 20 min at room
temperature; the reaction mixture was then loaded onto a 6%
nondenaturing acrylamide gel and subjected to electrophoresis at
160 V for 90 min, in 0.4 X Tris-borate-EDTA buffer. Gels were
transferred to Biodyne B nylon membranes (0.45 mm) (Thermo
Scientific, IL) in 0.4 X Tris-borate-EDTA buffer at 80 V for 1 hr.
Unbound probe and RNA-protein bound signals were detected
using a stabilized streptavidin-HRP conjugate antibody in a
chemiluminescent nucleic acid detection module kit (Thermo
Scientific, IL), per the manufacturer’s instructions, and exposed to
BIOMAX MR films from Kodak.
Dephosphorylation of hTTP
Some samples of hTTP lysates overexpressed in HEK 293
cells were dephosphorylated with calf intestinal alkaline phospho-
tase (CIAP) (Invitrogen Corp., Carlsbad, CA) as described
previously [35].
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For in gel digestion of proteins, phosphorylation sites from
eluted samples of hTTP from HEK-293 cells overexpressing Flag-
hTTP alone, or Flag-hTTP and HA-CIN85 together, were
analyzed by performing MALDI-MS and ESI-MS on hTTP
tryptic peptides that were extracted from the polyacrylamide gels.
In brief, clarified supernatants of cell lysates in RIPA buffer were
subjected to a Flag-peptide affinity column, and hTTP was eluted
using 3XFlag peptides as per the manufacturer’s instructions
(Sigma). Gel bands were excised manually and digested with
trypsin (Promega) for 8 h in an automated fashion with a Progest
robotic digester from Genomic Solutions. Resulting peptides were
lyophilized and then resuspended in 35 ml of 0.1% formic acid.
For phosphopeptide enrichment, TiO2 tips (Glygen) were
employed using essentially the manufacturer’s recommended
protocol.
A variety of MS and affinity techniques were employed in efforts
to identify sites of phosphorylation on hTTP. ESI-MS (see below)
was performed on hTTP peptides that were from solution digests
or extracted from polyacrylamide gels with and without MOAC
enrichment. Candidate phosphorylated peptides determined by
automated database searching were manually validated. Once
sites were identified, nanoLC-ESI-MS experiments were per-
formed on hTTP digests in efforts to obtain information on the
relative extent of phosphorylation at the identified site using
approaches essentially as described [78].
NanoLC-ESI-MS and MS/MS analyses were performed on
hTTP digests using an Agilent 1100 nanoLC system on-line with
an Agilent 6340 ion trap mass spectrometer with the Chip Cube
Interface. Briefly, 20 ml of hTTP digest were loaded onto an
Agilent C18 chip (75 mm643 mm) followed by a 15 min wash of
5% acetonitrile, 0.1% formic acid. Peptides were eluted by
applying a linear gradient from 5% acetonitrile, 0.1% formic acid
to 50% acetonitrile, 0.1% formic acid to the column over 45 min.
This was followed by a 5 minute gradient from 50% acetonitrile,
0.1% formic acid to 95% acetonitrile, 0.1% formic acid and then a
10 minute hold at 95% acetonitrile, 0.1% formic acid. The mass
spectrometer was used in the positive ion, standard enhanced
mode and included settings of a mass range from 200 to 2200 m/
z, an ionization potential of 2.1 kV, an ICC smart target of
100000 ions accumulated in the trap or 200 milliseconds of
accumulation, and a 1.0 volt fragmentation amplitude. MS/MS
data were acquired using a data dependent acquisition format,
with the six most abundant ions from each MS scan further
interrogated by MS/MS. The automated switching for MS/MS
required a threshold of 5000 counts.
For automated database searching, peak lists were generated
from the data obtained from each nanoLC-ESI-MS/MS analysis
using the Data Extractor feature of the SpectrumMill software
from Agilent. The resulting extracted data were then searched
against the NCBI non-redundant database using the MS/MS
Search function in the SpectrumMill software. Search settings
included enzyme specificity with up to two missed cleavages
allowed, a precursor ion mass tolerance of 1.5 Da, a product ion
mass tolerance of 1.0 Da, variable methionine oxidation, serine,
threonine, and tyrosine phosphorylation, and a minimum matched
spectral intensity of 70%. Sequence assignments of MS/MS
spectra were manually validated.
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